Anglican: Obtained the registration certificate for Diclofenac Sodium Enteric-coated Tablets and the supplementary approval for the application of Sacubitril Valsartan Sodium Tablets.

Yangli Kang announced that it recently received the "Drug Registration Certificate" for Enteric-coated Sodium Diclofenac Tablets and the "Drug Supplementary Application Approval Notice" for Sacubitril Valsartan Sodium Tablets issued by the National Medical Products Administration. The specification of Enteric-coated Sodium Diclofenac Tablets is 25mg, with the approval document valid until December 8, 2030, deemed equivalent to passing a consistency evaluation; the specification of Sacubitril Valsartan Sodium Tablets has been increased to 100mg, with the approval document valid until June 27, 2029. This approval will enrich the company's product pipeline and specifications, but drug sales are subject to uncertainty due to factors such as policies and market conditions.